Summary
Alembic Pharmaceuticals and NATCO Pharma have received tentative USFDA approval for generic Olaparib tablets, a cancer drug with an estimated US market size of $1.4 billion. Alembic will distribute the product, manufactured by NATCO Pharma, though commercial launch is contingent on ongoing litigation.